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Abstract: Intravenously administered liposomes and other nano-sized particles are known to 
passively accumulate in solid tumors via the enhanced permeability and retention (EPR) 
effect, which is extensively explored toward the improvement of diagnosis and drug delivery 
in oncology. Agent extravasation into tumors is often hampered by the mononuclear 
phagocytic and renal systems, which sequester and/or eliminate most of the nanoparticles 
from the body. Dynamic imaging of the tumor microcirculation and bolus perfusion can thus 
facilitate optimization of the nanoparticle delivery. When it comes to non-invasive 
visualization of rapid biological dynamics in whole tumors, the currently available pre-
clinical imaging modalities are commonly limited by shallow penetration, lack of suitable 
contrast or otherwise insufficient spatial or temporal resolution. Herein, we demonstrate the 
unique capabilities of a combined epi-fluorescence and optoacoustic tomography (FLOT) 
system for characterizing contrast agent dynamics in orthotopic breast tumors in mice. A 
liposomal indocyanine green (Lipo-ICG) preparation was administered intravenously with the 
time-lapse data continuously acquired during and after the injection procedure. In addition to 
the highly sensitive detection of the fluorescence agent by the epi-fluorescence modality, the 
volumetric multi-spectral optoacoustic tomography readings further enabled resolving deep-
seated vascular structures with high spatial resolution and hence provided accurate readings 
of the dynamic bio-distribution of nanoparticles in the entire tumor in 3D. The synergetic 
combination of the two modalities can become a powerful tool in cancer research and 
potentially aid the diagnosis, staging and treatment guidance of certain types of cancer in the 
clinical setting. 
© 2019 Optical Society of America under the terms of the OSA Open Access Publishing Agreement 
1. Introduction 
Nanoparticles injected into tumor-bearing animals are likely to leak into the extracellular 
matrix through the abnormal vessels formed during tumor growth. Such neo-vascular network 
is characterized by a hierarchical disorganization exhibiting a convoluted structure including 
irregular branching, arteriovenous shunts and a fenestrated endothelium with relatively large 
gaps between cells [1]. Particularly, mother vessels originating from normal venules and 
capillaries are composed of a thin layer of endothelial cells featuring abnormal hyper-
permeability to plasma proteins [2]. This, along with the fact that blood flow is reduced by 
elevated levels of viscosity in such vessels, facilitates extravasation of nanoparticles smaller 
than ~200 nm [3,4]. Since most tumors lack effective lymphatic drainage, the nanoparticles 
remain in tissue and are considered to passively target the tumor via the so-called enhanced 
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permeability and retention (EPR) effect [5]. There are however two biological barriers that 
hamper nanoparticle delivery into the tumor. The first one is the renal system, which excretes 
molecules and nanoparticles with a hydrodynamic diameter smaller than ~5.5 nm [6]. The 
second barrier is the mononuclear phagocytic system consisting of a network of organs 
(particularly the liver and spleen) containing cells that can phagocytize larger nanoparticles 
[7]. A recent review on the literature on nanoparticle delivery to tumors from the last decade 
showed that only 0.7% (median) of the injected nanoparticles reach the target tumor (0.6% for 
passive targeting) [8]. Then, it appears that optimizing the nanoparticles to enhance the 
extravasation during the first passes through the tumor microvasculature is a key factor in 
achieving more efficient tumor targeting. 
Medical imaging technologies have experienced major advancements in the last few 
decades and currently play an essential role in oncology [9,10]. The EPR effect was first 
described by visualizing the accumulation of an Evans blue complex with albumin into mouse 
tumor tissues [11], and imaging technologies continue to be widely used for a better 
characterization and understanding of this phenomenon [12]. X-ray imaging (planar or 
computed tomography (CT)), magnetic resonance imaging (MRI), nuclear medicine (single 
photon emission tomography (SPECT) and positron emission tomography (PET)), ultrasound 
(US) and optical imaging are routinely being used for the diagnosis, staging and treatment of 
cancer [13]. All these technologies offer certain capabilities for monitoring contrast agent 
perfusion and extravasation, but are also afflicted by several limitations. The generally low 
temporal resolution of tomographic imaging modalities such as CT, MRI and PET hinders 
proper characterization of the EPR dynamics [14]. US provides high-frame-rate imaging, but 
extravasation of most US contrast agents is commonly hindered by their large size [15]. 
Optical imaging methods, particularly fluorescence-based, can detect a large variety of 
contrast agents in real time with high sensitivity and further enable intraoperative monitoring 
of cancer-related surgeries [16].Yet, strong light scattering in biological tissues leads to loss 
of spatial resolution and inability to resolve depth. Optoacoustic (OA) imaging has emerged 
in the 2000s as a technology capable of providing functional and molecular imaging 
capabilities that can be used for visualizing fluorescent and non-fluorescent light-absorbing 
agents [17–24]. OA further enables high-resolution mapping of vascular networks [25], while 
state-of-the-art systems provide very high imaging rates in the order of hundreds to thousands 
of Hertz [26]. Overall, OA offers unique capabilities for cancer research and is growingly 
being used in small-animal studies aiming at providing new insights on tumor growth and 
development. A thorough comparison of the sensitivity limits of OA imaging with respect to 
other fluorescence-based optical imaging techniques is yet to be established [27], in particular 
in connection to detecting small amounts of nano-agents retained by (or targeted to) solid 
tumors. 
Herein, we exploit the synergistic advantages of a combined two dimensional (2D) epi-
fluorescence and real-time volumetric multi-spectral optoacoustic tomography (FLOT) 
system for high-frame-rate visualization of the dynamics of nanoparticles as they perfuse in 
the tumor microvasculature. Indocyanine green (ICG) was encapsulated into liposomes to 
form ~110 nm nanoparticles. The liposomal ICG (Lipo-ICG) solution was injected 
intravenously in mice featuring orthotopic breast tumors and a sequence of hybrid FLOT 
images was acquired at 10 frames per second. The system can efficiently analyze the 
pharmacokinetics of the particles early-on in circulation during the first passes of the bolus 
through the tumor vasculature. Additionally, it is shown that the suggested approach enables 
sensitive detection of extravasation at different time points as well as oxygen saturation 
mapping in the entire tumor volume. 
                                                                      Vol. 10, No. 10 | 1 Oct 2019 | BIOMEDICAL OPTICS EXPRESS 5094 
2. Materials and methods 
Hybrid epifluorescence and optoacoustic imaging system 
The hybrid FLOT system used for mouse breast tumor imaging is depicted in Fig. 1(a). A 
custom-made fiberscope (Zibra Corporation, Westport, MA) was used to excite both 
fluorescence and optoacoustic responses and acquire epi-fluorescence images through the 
cylindrical cavity of a spherical ultrasound array [28]. The fiberscope consists of a 1.4 mm 
diameter optic image guide made of 100,000 fibers and an illumination bundle composed of 7 
fibers having 600 µm core diameter and 0.4 numerical aperture (NA) each. An emission filter 
was placed in front of an electron multiplying charged-coupled device (EMCCD)-based 
camera (Andor Luca R, Oxford Instruments, UK) to selectively collect the fluorescence 
responses transmitted through the optic guide. The ultrasound array (Imasonic SaS, France) 
was used to collect OA signals with 512 piezocomposite elements having ~2.5 mm diameter, 
5 MHz central frequency and ~100% detection bandwidth [29].The elements are uniformly 
distributed on a spherical surface with 40 mm radius and 140° angular coverage (1.3π solid 
angle). An optical parametric oscillator (OPO)-based short-pulsed laser (Innolas Laser 
GmbH, Germany) was guided through the illumination bundle of the fiberscope, 
simultaneously exciting OA and fluorescence responses. 
Fluorescence and OA images were recorded for 15 minutes. The acquisition commenced 
~20 s before the tail vein injection of Lipo-ICG. The wavelength and the pulse repetition 
frequency (PRF) of the laser were tuned to 780 nm and 10 Hz, respectively. One-minute 
duration FLOT data was additionally recorded at 30, 45 and 60 min post Lipo-ICG injection. 
For this, the excitation wavelength was set at 780 nm for fluorescence imaging while the 
corresponding OA data was recorded at five excitation wavelengths of 720, 755, 780, 820 and 
855 nm. 
Optoacoustic image reconstruction and multi-spectral unmixing 
Three-dimensional optoacoustic images were obtained from the acquired time-resolved 
signals with a graphics processing unit (GPU) implementation of a back-projection formula 
[30]. Prior to reconstruction, the signals were deconvolved with the electrical impulse 
response of the transducer and band-pass filter to suppress low frequency bias and high 
frequency noise. The reconstructed images at different wavelengths were averaged and then 
further processed to unmix the distribution of the injected contrast agent and estimate the 
blood oxygen saturation levels. For this, a linear model assuming that the light fluence 
distribution does not significantly change with wavelength was used. Although more accurate 
approaches have been suggested [31], this method has shown to provide sufficient accuracy 
for mapping oxygen saturation levels for spherical transducer arrays and the relatively 
shallow depth of the tumors [32]. 
Animal models for the experiments 
Experiments were performed with the MDA-MB-231 murine breast tumor model. 
Specifically, two 4-week old adult female athymic nude-Foxn1 nude mice (Harlan 
Laboratories LTD, Switzerland) were inoculated subcutaneously in the breast region next to 
the left hind leg (Fig. 1(b)) with 3 million cells in 30 µL PBS. The mice were imaged after 
tumors reached a size of approximately 10 mm diameter (10 days after inoculation). Tail-vein 
injection of 100 µl of 0.5 mg/ml Lipo-ICG solution in water was performed as described 
above. During the experiments, the mice were anesthetized with isoflurane (2.5% v/v for 
induction followed by 1.5-2.0% v/v) in 100% O2 at a flow rate of ~0.8 l/min. After 
completion of the measurements, the mice were euthanized while still being under anesthesia. 
Animal handling and experimentation were conducted in full accordance with the directives 
on animal experimentation of the Helmholtz Center Munich and with approval from the 
Government District of Upper Bavaria. 
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 Fig. 1. Experimental set-up and Lipo-ICG characterization. (a) Schematic of the FLOT system. 
(b) Photograph of the mouse carrying the MDA-MB-231 breast tumor. (c) Electron 
microscope image of the Lipo-ICG contrast agent. (d) Spectrophotometer- and OA-based 
measurements of the absorption spectrum of Lipo-ICG with a concentration of 50 µg/ml. 
Liposomal ICG preparation 
Lipo-ICG was prepared using the reverse phase evaporation method [33]. In brief, 50 mg 
DSPC, 40 mg cholesterol and 5 mg DSPE-PEG2k were dissolved in 5 mL dichloromethane, 
while 5 mg ICG was separately dissolved in 10 mL Milli-Q water. These two solutions were 
mixed together and sonicated for 120 s. The organic solvent was subsequently evaporated 
from the mixture by rotary evaporation. An ivory emulsion was subsequently obtained. In 
order to remove the unentrapped ICG, the dispersion was subjected five times to 
ultrafiltration (MWCO = 100K, 5000 rpm, 10 min). The final dispersion was passed through 
an extruder with polycarbonate membrane filters (450 nm pore size). Transmission electron 
microscopy (TEM) image of the engineered Lipo-ICG with particle size in the 110 nm range 
is shown in Fig. 1(c). The encapsulation efficiency of ICG was 94.62 ± 0.74%, as measured 
after ultracentrifugation with a UV-visible spectrophotometer. 
3. Results 
We first compared the absorption spectrum of Lipo-ICG with a concentration of 50 µg/ml as 
measured by a conventional spectrophotometer (Ocean Optics Inc., USA) to its OA spectrum. 
While the spectrophotometer measurement featured an absorption peak at 780 nm 
wavelength, as expected for ICG in water, the peak was shifted by ~10 nm in the OA 
measurement (Fig. 1(d)). The discrepancy can be attributed to the fluorescence leakage into 
the light sensor during the absorbance measurement with the spectrophotometer. 
Experimental results of time-lapse imaging of the Lipo-ICG perfusion in mouse tumors 
are presented in Fig. 2. A weighted moving averaging of 5 frames was applied prior to 
reconstruction to reduce per-pulse signal fluctuations. For easier interpretation, the 
fluorescence intensity was superimposed onto the top (x-y) projection of the reconstructed 
OA volumes (Fig. 2(a)). OA image were normalized to the maximum value of the entire 
recorded image sequence. Fluorescence images were instead normalized individually to show 
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enhanced signal distribution within the FOV. The dashed circle indicates the effective 
fluorescence field of view (FOV) with a diameter of ~8 mm. Since OA is able to resolve 
high-resolution 3D information, different voxels along z axis can be selected for each point in 
the top (x-y) projection, which shows differential signal trends as a function of depth (Figs. 
2(b)-(e)). Note that depth-1 is located in the most superficial area while depth-4 corresponds 
to the deepest location in the tumor. Due to their inherently 2D (surface-weighted) and diffuse 
nature, the fluorescence responses solely reveal the global signal trend across the entire 
tumor, i.e. sharp signal increase followed by a slow exponential decay. This is obviously 
associated to agent clearance from the blood circulation. Overall, the time profiles extracted 
from the self-normalized fluorescence images have an ascending trend, indicative of the agent 
accumulation in the tumor via the EPR effect. The OA signal intensity profiles at shallow 
regions generally correlate with the fluorescence responses, i.e. sharp decrease after Lipo-ICG 
bolus perfusion through the vessel followed by a slow increase (see e.g. profile p1 versus 
depth-1 in Fig. 2(b)). Deeper located voxels for the same x-y coordinates (depth-2 and depth-
3) exhibit OA signal increase after Lipo-ICG perfusion, which appears to substantiate the 
observation of the EPR effect. Both fluorescence and OA signals at another superficial 
location (p2 in Fig. 2(c)) have a similar decreasing trend, which can be ascribed to the slow 
dynamics of microvascular structures. However, the OA trace at a greater depth (depth-4) 
remains at an elevated level after the dye perfusion, which may again correspond to Lipo-ICG 
leakage and accumulation via EPR. The same effect is also observed in the depth resolved 
OA signal traces at location p3 plotted in Fig. 2(d) and location p4 plotted in Fig. 2(e). 
 
Fig. 2. Time lapse images of mouse breast tumor perfusion. (a) Maximum intensity projection 
of the tumor at different time points in x-y and y-z view. In the x-y view, fluorescence signal is 
superimposed onto the OA signal. The dotted circle indicates the effective fluorescence FOV 
with a diameter of ~8 mm. (b) – (d) Signal profiles from the three points p1-p3 indicated in 
panel (a). Note that in contrast to the surface-weighted fluorescence measurements, OA 
imaging can resolve 3D information, thus the OA signal traces are also plotted at different 
depths: depth-1 is located in the most superficial area while depth-4 corresponds to the deepest 
region in the tumor. Scale bar 1 mm. 
Differences between perfusion profiles captured by the two modalities can be best viewed 
on a differential scale shown in Fig. 3. Those were calculated by subtracting the background 
signal taken as the average of 50 frames before injection of the agent. The light box indicates 
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the injection time window. Note that the images in Fig. 3 were normalized to the maximum of 
the corresponding sequence to better reveal the signal variations. The temporal profiles for 
three points of interest (p1 - p3 as indicated in Fig. 3(a)) are plotted in Figs. 3(c)-3(e). For 
each point, depth-1 corresponds to a superficial region while depth-2 is located at a deeper 
region in the tumor. A good match between the FL and OA profiles is manifested for points 
p1 and p2 located within main vascular structures (Figs. 3(c), (d)). However, the perfusion 
dynamics differs significantly in point p2 located far away from the major vasculature (Fig. 
3(e)). This can be attributed to the lack of spatial and depth resolution of the FL modality, 
which suffers from extensive photon scattering in tissues. 
 
Fig. 3. Sensitivity comparison of OA and FL for Lipo-ICG detection. (a) MIPs of the OA 
images along the z and x directions for 3 different time points. (b) FL images for the same time 
points in (a). (c) – (e) Signal profiles from points p1-p3 indicated in panel (a), respectively. 
Scale bar 1 mm. 
Figure 4 displays spectral unmixing results from the multispectral OA acquisition 30 min 
post Lipo-ICG injection. For the unmixing, only major endogenous chromophores were taken 
into consideration, namely oxy- (HbO2) and deoxy-hemoglobin (Hb), along with Lipo-ICG. 
As expected, the HbO2 component is predominantly concentrated in the blood vessels 
whereas Hb is mainly present in the tumor mass. The observed blood oxygen saturation (sO2) 
map is furthermore consistent with reported values, ranging from 60% to almost 100% in 
arteries and veins while dropping below 40% in the dermis [34]. In the unmixed Lipo-ICG 
image (Fig. 4(d)) the agent appears to be present both in major vessels and the tumor mass. It 
is important to take into account that cross-talk in the unmixing procedure may lead to 
erroneous interpretations, which is generally supported by the corresponding FL results 
shown in Fig. 4(e). 
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 Fig. 4. Multi-spectral optoacoustic imaging of tumors 30 min post injection of the liposomal 
ICG agent. Maximum intensity projections (MIPs) along the depth and lateral dimensions of 
the unmixed distribution of oxygenated hemoglobin (a), deoxygenated hemoglobin (b), oxygen 
saturation (c) and liposomal ICG (d). sO2 values below 30% were set to zero. (e) Fluorescence 
image of the tumor with the region of interest indicated by the dotted cycle in (d). 
4. Discussion and conclusions 
Despite its limited penetration depth and inferior spatial resolution, planar fluorescence 
imaging currently remains a workhorse in cancer research e.g. through its extensive use in 
longitudinal molecular imaging studies looking at accumulation of drugs or targeted probes 
[35]. Yet, our results indicate that planar fluorescence images merely represent a surface-
weighted signal integrated along different depths, which may result in misinterpretation of the 
underlying agent dynamics and biodistribution. The availability of InGaAs cameras has 
recently facilitated epi-fluorescence imaging in a new NIR window featuring less optical 
scattering [36] with new contrast agents having fluorescent emission in this spectral window 
constantly under development [37]. These developments have led to an enhancement of the 
resolution and contrast of epi-fluorescence images, although the inherently 2D nature of this 
modality still limits its quantification capabilities. 
The hybrid FLOT method can facilitate more accurate interpretation of agent perfusion 
and biodistribution in solid tumors while also aiding the development of new nanoparticles 
with favorite extravasation properties and more efficient tumor targeting capacities. Since the 
generated ultrasound waves undergo significantly less attenuation than light for the detected 
frequency bandwidth, the signal decay with depth is lower for OA and hence it can potentially 
reach deeper regions [27]. It was further shown that tomographic imaging capacity of OA can 
efficiently resolve fine vascular structures in the entire tumor. The Lipo-ICG perfusion could 
be characterized in the sequence of OA images by analyzing the time profiles at different 
points of the vascular network within and around the tumor. Good correspondence to epi-
fluorescence perfusion profiles was found at shallow located vessels in the tumor. However, 
the profiles differed significantly at deeper locations and outside major vasculature, which is 
attributed to the lack of depth resolution and diffuse nature of the epi-fluorescence images. 
Overall, the dynamic visualization of the accumulation and washout process of Lipo-ICG 
with the hybrid system can provide important information on the probe distribution, 
permeation, retention and their elimination from the body. Cross-validation between epi-
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fluorescence and OAT further substantiates the observation of the EPR effect within the 
tumor. 
Apart from monitoring of tumor perfusion and EPR effects, the FLOT system additionally 
allows for mapping oxygen saturation in the tumor. This may aid the characterization of 
tumor heterogeneity and detect low levels of oxygen partial pressure. Tumor hypoxia is one 
of the major causes of tumor resistance to treatments and a better characterization of its 
dynamic oxygenation behavior may shed light onto tumor development. The resolution of the 
OA system employed in this work enabled visualizing relatively large vessels in the tumor. 
This can be scaled by introducing a high frequency detection array [38], thus potentially 
enabling anatomic characterization of finer microvascular structures and neo-vascularization, 
an important hallmark of cancer. The hybrid system may additionally become a useful clinical 
tool for cancer diagnostics, intraoperative navigation or treatment monitoring [39,40]. While 
ICG is a clinically-approved small molecule dye, other agents and types of encapsulation 
strategies like Lipo-ICG must still overcome regulatory challenges. 
In conclusion, by efficiently integrating epi-fluorescence and optoacoustic imaging, the 
advantages of both modalities can be synergistically exploited to provide more 
comprehensive and cross-validated readings of key biomarkers of tumor development. FLOT 
is thus expected to find broad applicability in cancer research as well as other areas involving 
tracking of fast biological dynamics, such as cardiac and brain imaging [41,42]. 
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